The Uromigos
The Uromigos
Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Podcast'in sitesini ziyaret etmeyi ve yapımcısını desteklemeyi unutma: www.uromigos.org
Nereden dinlenir?
Uygulamada podcast'ler Replaio Radio Çok yakındaPodcast'ler çok yakında uygulamaya geliyor. Şimdi yükle ve podcast'lere yepyeni bir bakışı ilk gören sen ol
Ücretsiz yükle
Android 5 Mn+ indirme · 4,8 puan
iOS yakında
Bölümler
Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap 21.07.2025 27:49
Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.
Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials 14.07.2025 43:59
Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.
Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers? 07.07.2025 45:46
Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.
Episode 428: ASCO 2025 Recap 16.06.2025 54:20
Brian, Tom and Silke discuss their highlights form ASCO 2025
Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC) 13.06.2025 40:27
Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.
Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC 06.06.2025 37:22
Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025
Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI 04.06.2025 19:39
Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone
Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session 02.06.2025 30:10
Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC 01.06.2025 30:49
Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Episode 422: ACSO 2025 - ctDNA data from NIAGARA 01.06.2025 32:40
Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.
Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer 01.06.2025 34:49
Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.
Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer 01.06.2025 24:18
Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation
Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study 31.05.2025 23:49
Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
Episode 418: ASCO 2025 - Biomarkers in RCC 31.05.2025 44:55
David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.
Episode 416: ASCO 2025 Preview 19.05.2025 40:43
Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025
Episode 413: The Uromigos Score for Advanced Prostate Cancer 12.05.2025 37:02
Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC 05.05.2025 28:52
Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1 05.05.2025 37:20
Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.
Episode 411: Live from EIKCS in Amsterdam - RCC Highlights 03.05.2025 20:26
Viktor Grunwald joins to discuss the new data session from EIKCS
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC 26.04.2025 47:27
Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting
Episode 407: Drug Development in China: Part 2 of 2 21.04.2025 25:21
Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China
Episode 406: Drug Development in China: Part 1 of 2 14.04.2025 30:02
Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.
Episode 405: The Good News About Cancer podcast 11.04.2025 17:53
Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.
Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands 07.04.2025 27:09
Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinical practice.
Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands 02.04.2025 37:41
Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer
Benzer podcast'ler
The Uromigos podcast'ini Replaio'da dinle
Radyo ve podcast'ler tek uygulamada - ücretsiz, kayıt gerektirmez. Bugün yükle ve lansmanı kaçırma
Replaio bir podcast yayıncısı değildir; program adları, kapak görselleri ve ses içerikleri yazarlarına aittir ve herkese açık RSS beslemeleri aracılığıyla dağıtılır
